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Her2 alterations in muscle-invasive 
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Although the introduction of novel targeted agents has improved patient outcomes in several human 
cancers, no such advance has been achieved in muscle-invasive bladder cancer (MIBC). However, recent 
sequencing efforts have begun to dissect the complex genomic landscape of MIBC, revealing distinct 
molecular subtypes and offering hope for implementation of targeted therapies. Her2 (ERBB2) is one 
of the most established therapeutic targets in breast and gastric cancer but agents targeting Her2 have 
not yet demonstrated anti-tumor activity in MIBC. Through an integrated analysis of 127 patients from 
three centers, we identified alterations of Her2 at the DNA, RNA and protein level, and demonstrate 
that Her2 relevance as a tumor driver likely may vary even within ERBB2 amplified cases. Importantly, 
tumors with a luminal molecular subtype have a significantly higher rate of Her2 alterations than those 
of the basal subtype, suggesting that Her2 activity is also associated with subtype status. Although 
some of our findings present rare events in bladder cancer, our study suggests that comprehensively 
assessing Her2 status in the context of tumor molecular subtype may help select MIBC patients most 
likely to respond to Her2 targeted therapy.
Muscle invasive bladder cancer (MIBC) is a highly aggressive disease, with a 5 year survival rate post-diagnosis 
of approximately 50%1,2. Although the implementation of neoadjuvant chemotherapy extended overall patient 
survival3,4, prior to the recent advent of immune checkpoint inhibitors, no relevant new therapies have been 
introduced in the last 3 decades5,6. This is in stark contrast to several other major cancers7–12.
Her2 (gene name: ERBB2) is a member of the epidermal growth factor receptor (EGFR) family, and one of the 
best-known therapeutic targets in oncology. Her2 can activate intracellular pathways that promote proliferation, 
survival, mobility and invasiveness of tumor cells and these aggressive oncogenic features translate into reduced 
survival in patients with Her2-overexpressing breast and gastric cancers11,13. In these cancers, gene amplification 
is the primary mechanism for Her2 overexpression and Her2 targeted therapies (e.g. trastuzumab or lapatinib) 
have become a standard treatment in appropriate tumors7,11. MIBC has the third highest rate of ERBB2 amplifi-
cation (after breast and gastric cancer)14 and demonstrates frequent Her2 overexpression15,16. Even so, anti-Her2 
treatments in MIBC have not been as encouraging17–20 and despite best practice patient selection by fluorescence 
in-situ hybridization (FISH) and immunohistochemistry (IHC), question whether bladder cancer can respond 
to Her2 targeted therapy. However, these instruments for patient selection have been developed and shown to be 
successful in patients with breast or gastric cancers and might not be optimal in those with MIBC.
The identification of tumor molecular subtypes by four separate research groups is one of the most impor-
tant recent discoveries in MIBC14,21–23. On a higher level, all represent a division into basal and luminal tumors. 
1Department of Urology, University of Bern, Bern, Switzerland. 2Vancouver Prostate Centre, Department of 
Urologic Sciences, University of British Columbia, Vancouver, Canada. 3Department of Urology, University Hospital 
of Southampton, Hampshire SO16 6YD, UK. 4Institute of Pathology, University of Bern, Bern, Switzerland. 
5Department of Urology, Institute of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan. 
6GenomeDx Biosciences, Inc., Vancouver, British Columbia, Canada. Correspondence and requests for materials 
should be addressed to R.S. (email: r_seiler@gmx.ch)
Received: 06 October 2016
accepted: 12 January 2017
Published: 16 February 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:42713 | DOI: 10.1038/srep42713
Within this framework, each system made specific subclassifications. For example, through RNA profiling of hun-
dreds of MIBC tumors, The Cancer Genome Atlas (TCGA) Research Network identified four distinct clusters that 
are each associated with specific biological characteristics, pathway activities, and clinical behavior/outcomes14. 
Clusters I and II have predominantly luminal characteristics, express markers of urothelial differentiation such 
as uroplakins, express the same cytokeratins as the luminal layer of the normal urothelium (KRT18 and KRT20) 
and exhibit a strong peroxisome proliferator activator receptor (PPAR) pathway activation. Cluster III and IV 
represent basal tumors, identified by squamous features, expression of cytokeratins (KRT14 and KRT5) and a 
higher proliferation rate than luminal tumors. These resemble the basal/stem cell compartment of the normal 
urothelium. In addition, cluster IV tumors show the highest immune infiltration. As a consequence, contem-
porary biomarker studies must account for the possibility that the baseline characteristics, biological role and 
significance of genomic alterations may vary between molecular subtypes.
We hypothesized that an integrated approach to Her2 characterization in MIBC may better guide patient pri-
oritization for targeted therapy. Therefore, we assembled a cohort of MIBC patients from three academic centers, 
identified Her2 alterations at the DNA, RNA and protein level and dissected the relationship of alterations to each 
other and in the context of the TCGA clusters. We demonstrate that it is necessary to analyze Her2 on all three 
levels to sufficiently characterize all alterations, and suggest that such comprehensive analysis will provide optimal 
patient stratification for future Her2-targeted trials.
Material and Methods
Patient cohort. We selected a retrospective consecutive cohort of 127 patients from three tertiary centers 
(Supp Table 1). All patients were diagnosed with muscle-invasive urothelial bladder cancer and clinical staging 
included computed tomography (CT) scan of the abdomen and pelvis, chest x-ray (or chest CT) and bone scan. 
All patients received at least 3 cycles of neoadjuvant chemotherapy (NAC) with gemcitabine and cisplatin prior 
to cystectomy and pelvic lymph node dissection. Patients receiving other chemotherapy regimens or not under-
going cystectomy were excluded. Follow-up varied according to centre, but usually included evaluation at 3 and 6 
months postoperatively, every 6-months up to 5 years and yearly thereafter. 
Pathology. Pre-chemotherapy bladder tumor specimens from transurethral resection (TURBT) were used 
for analysis. All tissue slides from each patient were re-evaluated for this study by two investigators blinded 
to patient outcome. One haematoxylin and eosin stained section was taken per tissue block and tumor grade 
was assessed microscopically. In combination with clinical parameters, all tumors were staged according to the 
seventh International Union Against Cancer (UICC) classification of 200924. A tissue microarray (TMA)25 was 
constructed with two cores per patient from the invasive tumor component.
Fluorescence in-situ hybridization (FISH) and Immunohistochemistry (IHC). Two sections of 3 μm 
thickness were taken and the FISH reactions were performed according to the FISH Her2 PharmDx (DAKO) 
protocol. The kit contains a mixture of Texas Red-labeled DNA cosmid clones of the Her2 amplicon and a mix-
ture of fluorescein labeled peptide nucleic acid probes targeting the centromeric region of chromosome 17. The 
slides were processed according to the manufacturer’s protocol: after deparaffination, sections were immersed in 
pretreatment solution at 95 °C for 20 minutes followed by pepsin enzymatic digestion (15 minutes) at room tem-
perature. Her2/CEN-17 probe was applied and denatured at 82 °C for 5 minutes. Hybridization was performed 
overnight at 45 °C. Stringent washes were performed followed by 4,6-diamidino-2-phenylindole staining. Thirty 
tumor nuclei were evaluated per tissue spot and assigned as negative, equivocal or amplified (Fig. 1A and B and 
Supp Figure 1A and B) according to the recommendations of the American Society of Clinical Oncology/College 
of American Pathologists26 (Her2/CEP17 ratio <2.0 and Her2 copy number <4.0: negative, ratio <2.0 and Her2 
copy number ≥4.0 and <6.0: equivocal, ratio ≥2.0 or copy number ≥6.0: amplified).
The original Hercep Test™ was used for immunohistochemical Her2 protein detection. Her2 expression per 
tissue spot was classified according to the modified DAKO criteria: negative (0/1+), equivocal (2+) and positive 
(3+) (Fig. 1C and D and Supp Figure 1C and D) with a cut-off for score 3+ of more than 10% strongly positive 
cells26.
All FISH and IHC staining were performed at the Institute of Pathology, University of Bern, Switzerland. This 
laboratory is certified, has extensive Her2 IHC and FISH expertise and takes part in external proficiency testing.
mRNA Expression. Total RNA was extracted from a 1 mm diameter core punch of the tumor with the 
RNeasy FFPE kit (Qiagen, Valencia, CA), followed by amplification and labeling with the Ovation WTA FFPE 
system and Encore Biotin Module (both NuGen, San Carlos, CA), respectively. cDNA hybridization to GeneChip 
Human Exon 1.0 ST oligonucleotide microarrays (Affymetrix, Santa Clara, CA) was performed according to the 
manufacturer’s recommendations. The Affymetrix Power Tools package was used for quality control27 and mRNA 
expression data was normalized using SCAN28. This analysis was performed by GenomeDx Biosciences, a Clinical 
Laboratory Improvement Amendments (CLIA)-certified laboratory. Array files are available from the National 
Center for Biotechnology Information’s Gene Expression Omnibus (NCBI–GEO) database (http://www.ncbi.
nlm.nih.gov/geo/) under GEO accession code GSE87304.
Genomic sequencing. DNA was extracted from TURBT specimens from the same cohort; tissue of 96 
specimens was available for DNA extraction. Extracted DNA (100 ng) was sheared to 100–400 bp by sonication 
and was subjected to end-repair, dA-addition, and ligation of indexed IonProton sequencing adaptors. Libraries 
were hybridization-captured using a pool of >24 000 individually synthesized 50-biotinylated DNA oligonucleo-
tides. In total, 83/96 TURBT specimens passed all QC metrics and had available data on exome DNA sequencing. 
Synonymous single nucleotide variants (SNV), as well as variants falling in UTRs and introns of ERBB2 were not 
considered. Non-synonymous (missense) SNVs were called when reported in COSMIC database or with a variant 
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read ≥10 and an allele frequency of ≥10%. All SNVs were validated visually. To determine Copy Number variations 
(CNV), data analysis was performed using Nexus Copy Number Software, Version 8.0 (BioDiscovery, Hawthorne, 
CA). Samples were processed using the Nexus NGS functionality (BAM ngCGH) with the FASST2 Segmentation 
algorithm to make copy number calls (a Circular Binary Segmentation/Hidden Markov Model approach). The 
significance threshold for segmentation was set at 5 × 10−6, also requiring a minimum of 3 probes per segment and 
a maximum probe spacing of 1000 between adjacent probes before breaking a segment. The logratio thresholds 
for single copy gain and single copy loss were set at +0.2 and −0.02, respectively. The logratio thresholds for gain 
of 2 or more copies and for a homozygous loss were set at +0.6 and −1.0, respectively. Tumor sample BAM files 
were processed with corresponding normal tissue BAM files. Reference reads per CN point (window size) was set 
at 8000. Probes were normalized to median. The genomic sequencing was performed at laboratory for advanced 
genomic analysis of the Vancouver Prostate Centre that uses validated and approved experimental protocols.
The number of samples available for each analysis is given in Supp Table 1.
The TCGA bladder cohort. The TCGA Bladder Urothelial Carcinoma dataset (n = 407) was downloaded 
from the Broad Institute Firehose Pipeline (http://gdac.broadinstitute.org) on May, 10, 2016. Genomic DNA 
sequencing with ERBB2 mutation calls (n = 407), CNV (n = 403), gene expression (n = 407), methylation analy-
sis (HM450, n = 407) and reverse phase protein assay (RPPA) data for protein expression (n = 339) were used. For 
analysis of clinical outcomes only patients without neoadjuvant chemotherapy were selected (n = 397). As above, 
SNVs that did not alter the amino acid code of ERBB2 were not considered. Missense SNVs were called when 
reported in COSMIC database or with a variant read ≥10 and an allele frequency of ≥10%.
Figure 1. Micrographs of ERBB2 FISH and IHC in bladder cancer samples. Micrographs show representative 
bladder cancer samples without (A) and with (B) ERBB2 amplification. ERBB2 yields a red signal while the 
chromosome 17 centromere is stained with green. Amplification is defined as a gene to centromere ratio ≥2.0 or 
copy number ≥6.0. Scale bar represents 10 μm. Representative immunohistochemical stains demonstrate Her2 
negative (C, score 0) and strongly positive bladder cancers (D, score 3+). Scale bar represents 200 μm.
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Molecular subtyping. In both cohorts (our NAC cohort and TCGA), gene expression data was used to 
assign tumors to the TCGA clusters. The original “Classification to Nearest Centroids” (ClaNC) model was used14.
Statistical analysis. Statistical analysis was conducted using R Software Package, version 3.1.0. For com-
parison of non-categorical data between two and more groups logistic regression (lr) was used, respectively. 
Categorical data were compared using exact Fisher’s test. Pearson correlation was performed to compare the cor-
relation between continuous parameters. Kaplan-Meier plots estimated overall survival (OS) from surgery to the 
date of death. Patients still living were censored at the date of the last follow-up. Patients were grouped into tertiles 
of expression for survival analysis stratified according to mRNA expression and RPPA data. Median follow-up 
was calculated using inverted Kaplan-Meier plots. All tests were with type I error probability of 5%.
Experimental protocol and ethics. All experiments protocols were approved by the respective institute 
performing the analysis. The clinical research ethics board of each institution approved this study and all patients 
consented to analysis of their tumor tissues (Bern, Switzerland KEK-Be 219/2015; Vancouver, Canada H09-
01628; Southampton, UK, 10/H0405/99).
Results
We assembled a cohort of 127 patients with MIBC from three centers. Clinical and pathologic characteristics as 
well as the number of samples subjected to each mode of analysis (FISH, mRNA expression, IHC) are provided 
in Supp Table 1. Tissue was derived from the pre-treatment TURBT, and all patients subsequently received NAC.
Association between ERBB2 gene amplification and expression. In the NAC cohort, FISH revealed 
that 16/83 tumors harbored ERBB2 amplification, while 24/127 had high Her2 protein expression by IHC (i.e. 
IHC score = 3). Samples with ERBB2 amplification had higher mRNA (p < 0.001) and protein expression 
(p < 0.001) (Fig. 2A and C), and mRNA and protein expression were significantly related to each other (p < 0.001) 
(Supp Figure 2A). However, not all amplified samples had high mRNA and protein expression. Six of 16 ampli-
fied samples had mRNA expression in the 1st tertile, and 10/16 had IHC scores of either 1 (n = 5) or 2 (n = 5). 
Furthermore, 19/67 non-amplified samples had a high mRNA expression (in the 3rd tertile) and 13/83 had an 
IHC Score 3, suggesting that gene amplification is not the sole driver of high Her2 expression in bladder cancer.
Findings in the TCGA bladder cohort were similar. mRNA and protein expression were significantly higher in 
amplified samples (p < 0.001, Fig. 2B and D) and correlation between mRNA and protein expression was strong 
(r: 0.72, p < 0.001, Supp Figure 2B). Not surprisingly, amplified cases had the lowest rate of ERBB2 methylation 
(p < 0.001, Supp Figure 2C). However, once again a significant proportion of patient tumors (115/403 and 99/339 
respectively) without ERBB2 amplification had high (in the 3rd tertile) mRNA and protein expression, and some 
patients with amplification did not have expression. This may be due to epigenetic factors, since the ERBB2 
amplified cases with the lowest mRNA expression had the highest rate of ERBB2 methylation (r: −0.62, p < 0.001, 
Supp Figure 2D).
SNVs in ERBB2 and relationship to amplification and expression. In the TCGA cohort, 45/407 (11%) 
tumours harbored missense SNVs in ERBB2 (Fig. 3A). Almost half of the mutations (20/45) fell in the Furin-like 
domain at position 310aa, a well-known mutational hotspot in ERBB2. Interestingly, 4 samples harboured both an 
SNV and concomitant amplification of ERBB2 (Fig. 3B). Three of these four samples had a mutant allele frequency 
of >85% which implies that the SNV was present in all alleles and therefore occurred before the amplification of 
ERBB2. mRNA and protein expression was not significantly different between samples with or without ERBB2 
mutations and the expression in samples with ERBB2 mutation appeared to be primarily dependent on copy number 
variance rather than the location of the mutation (Fig. 3C). Interestingly however, SNVs in the extracellular domain 
resulted in lower detected protein expression by RPPA compared to SNVs in the intracellular domain (Fig. 3D).
In our own dataset (the NAC cohort), 15/83 (18%) samples had a missense SNV in ERBB2 and 6/15 were in 
the Furin-like domain. The trend towards lower protein expression/detection in cases with mutation in the extra-
cellular domain was not significant. Importantly, ERBB2 copy number from FISH experiments were significantly 
related to the copy number estimation (log2[ratio]) from exome sequencing, providing robust inter-platform 
validation (p = 0.03, Supp Figure 2E–G).
We identified four tumors (across both cohorts) with ERBB2 amplification on the background of a relatively 
‘quiet’ overall genome copy number profile (one in our NAC: Fig. 3E, upper panel; three in TCGA: Supp Figure 3). 
Interestingly, three of these ‘exclusively’ ERBB2 amplified tumors had both high Her2 mRNA and protein expres-
sion, and were classified in cluster I. The sample with low mRNA and protein expression was classified in cluster 
III. None of these 4 samples had an ERBB2 SNV. All other samples with ERBB2 amplification also harbored CNV 
in other well-known oncogenes (e.g. CCND1, CCNE1) (Fig. 3E, lower panel).
Her2 in relation to TCGA clusters. In general, Her2 alterations were higher in the luminal TCGA clus-
ters (cluster I and II) compared to the basal clusters (cluster III and IV). In the TCGA cohort, the amplification 
rate and protein expression were highest in cluster I mRNA expression in cluster I and II was comparable but 
significantly higher than in cluster III and IV (Fig. 4). Our findings in the NAC cohort were virtually identical 
(Supp Figure 4). ERBB2 amplification, mRNA and protein expression were highest in cluster I. The amplification 
rate, mRNA and protein expression were lower in cluster II but still higher than in clusters III and IV.
Her2 and relation to clinical outcomes. None of the Her2 alterations, including SNVs, were related to 
pathologic response to NAC when response was defined as no residual muscle invasive disease (<ypT2N0). This 
was true when considering the entire cohort, and when considering the subtypes separately.
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In the entire NAC cohort, Her2 alterations including SNVs were not related to overall survival 
(Supp Figure 5A,C and E). Similar to findings in the NAC cohort Her2 alterations failed to stratify survival in the 
entire TCGA bladder cohort (Supp Figure 5B,D and F).
Discussion
Novel targeted therapies have revolutionized the treatment of many cancers. One of the best examples of this has 
been targeting of Her2 in overexpressing breast and gastric cancers7,29,30. However, no similar breakthroughs have 
been achieved in MIBC and inhibition of Her2 has demonstrated scant antitumor activity in clinical trials17–19. 
Targeting Her2 only in MIBC patients with Her2-overexpression and/or ERBB2 amplification was similarly 
Figure 2. Relationship between ERBB2 gene status and Her2 expression. (A) Bar plot demonstrating that 
ERBB2 amplified MIBC (determined by FISH) was enriched among the samples with high ERBB2 mRNA 
expression in our NAC cohort (lr, reference level [rl]: ERBB2 amplification status: normal). (B) ERBB2 amplified 
MIBC were similarly enriched among MIBC with a high mRNA expression in the TCGA bladder cohort. 
Somatic SNVs (indicated by arrows) were evenly distributed between cases with different mRNA expression (lr, 
mRNA expression vs. CNV, rl: hemizygous deletion). (C) Stacked bar plot showing that a significantly higher 
proportion of tumors with a Her2 protein expression score of 3+ harbored ERBB2 amplification by FISH, than 
tumors with scores of 0–2 (Fisher’s test). (D) Barplot showing Her2 protein expression in the TCGA bladder 
cohort, indicating significantly higher protein expression in patients with ERBB2 amplification. SNVs are 
indicated by arrows (lr, protein expression vs. CNV, rl: hemizygous deletion).
www.nature.com/scientificreports/
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Figure 3. Single nucleotide variants (SNV) in ERBB2 and relationship to amplification and expression. 
(A) Schematic of the ERBB2 coding region showing all somatic missense ERBB2 mutations detected in 
the TCGA bladder cohort. Twenty of 45 detected SNVs were located in the Furin-like domain. (B) Barplot 
showing the ERBB2 mutant allele frequency in four TCGA cases with both a mutation and concomitant 
ERBB2 amplification. Note that in 3/4 samples the mutant allele frequency was greater than 85%, suggesting 
that the SNV is present on all tumor amplicons and occurred prior to gene amplification. (C) Boxplot showing 
that among the 45 TCGA cases with ERBB2 mutations, mRNA expression levels were dependent on copy 
number status (lr, rl: hemizygous deletion). (D) Boxplot demonstrating that cases with Her2 extracellular 
domain mutations had a significant lower protein expression/detection than samples with intracellular 
domain mutations (lr, rl: extracellular SNVs). (E) Whole genome copy number profiles from two cases in our 
NAC cohort with ERBB2 amplification. Note that Case 1 (upper panel) appears to harbor isolated ERBB2 
amplification, while Case 2 (lower panel) exhibits multiple focal amplifications, including in other well-known 
oncogenes.
www.nature.com/scientificreports/
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unsuccessful17–20. The reason for this discrepancy between positive Her2 status and lack of antitumor activity is 
to date unclear. In this study we report that a comprehensive analysis of Her2 alterations at the DNA, RNA and 
protein levels reveals a complex landscape where only selected tumors have bona fide evidence of Her2 driver 
status. Prior clinical trials investigating Her2-targeted therapies in MIBC have been limited by their use of only 
FISH and IHC for patient selection17–19, and by the absence of Her2 cut-off levels validated specifically for bladder 
cancer. We posit that our findings may help to enrich future clinical trials investigating Her2-targeted therapies in 
MIBC with patients most likely to respond.
In general, an increase in ERBB2 copy number resulted in higher mRNA and protein expression in our own 
and the TCGA cohort. However, ERBB2 amplification was detected without overexpression of Her2 in some 
cases, while overexpression of Her2 was observed without ERBB2 amplification in others. This suggests that Her2 
overexpression is regulated by mechanisms other than gene amplification. Indeed, tumors with ERBB2 amplifi-
cation but low expression tended to have increased gene methylation, implying an important role for epigenetic 
control. Even among cases with concomitant overexpression, ERBB2 amplification may be a bystander event 
in most MIBC. MIBC is characterized by a high rate of genomic alterations14, reducing the probability that any 
individual alteration is a significant and non-redundant oncogenic driver. In rare cases, a combination of ERBB2 
amplification with high mRNA and/or protein expression and the absence of other major genomic alterations 
might be necessary to implicate Her2 as a driver in an individual tumor. In line with data from colorectal cancer31, 
this hypothesis could be verified with patient-derived primary xenografts using Her2 targeted agents. However, 
this hypothesis will ultimately need testing in clinical trials.
Our findings may suggest that SNVs in the extracellular domain of ERBB2 seem to result in a detection of 
lower protein expression compared to SNVs in the intracellular domain. This apparent reduced expression may 
in fact reflect lower affinity of the antibody to the mutated extracellular domain rather than a true alteration of 
protein expression. Likely, due to the smaller sample size we were not able to validate this finding in our NAC 
cohort. This finding also might have implications for clinical trials that select patients based on Her2 expression 
by IHC, where expression may appear artificially low. Furthermore, monoclonal antibodies such as trastuzumab 
and TDM-1 that target the extracellular domain of Her2 may be rendered ineffective by their inability to bind to 
the target. Interestingly, somatic mutations in the intracellular tyrosine kinase domain are reported to modulate 
Her2 signaling, resulting in increased Her2 activation and even resistance to lapatinib in bladder and breast 
cancer32,33. In addition, somatic ERBB2 SNVs have been discussed in the context of resistance to trastuzumab34. 
However, none such data exist from bladder cancer. Remarkably, different DNA alterations can occur sequen-
tially, few cases showed SNVs and coincident amplification of ERBB2 with different chronology, a phenomenon 
Figure 4. Relationship between Her2 alterations and TCGA clusters. (A) In the TCGA bladder cohort, 
ERBB2 copy number was significantly higher in luminal (cluster I and II) compared to basal tumors (cluster 
III and IV), but was similar between cluster I and II (Fisher’s test). (B) Consistent with our NAC dataset, 
ERBB2 mRNA expression in the TCGA bladder cohort was higher in cluster I and II than in cluster III and IV 
(lr, rl: cluster I). (C) Her2 protein expression, determined by RPPA was significantly higher in cluster I when 
compared to all other clusters (lr, rl: cluster I).
www.nature.com/scientificreports/
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that was also noted in a separate cohort with metastasising MIBC35. Taken together, beside amplification of the 
ERBB2-gene, it is likely that further somatic DNA alterations influence success when targeting Her2.
Our results suggest that alterations in ERBB2, that are not detectable by ERBB2/HER2 FISH or IHC alone, 
might have contributed to previously unsuccessful clinical trials of Her2-targeted therapies in MIBC patients. 
Algorithms for appropriate patient selection for Her2-targeted therapies are well-established and in routine clin-
ical use in breast cancer26. However, their direct transfer to MIBC appears to be confounded by the different 
spectrum of Her2 alterations and the specific context in which they occur (e.g. subtypes, highly mutated and/
or unstable genomes). Based upon our study, we propose a potential system for prioritizing patients with MIBC 
for different Her2-targeted therapies based on specific combinations of Her2 alterations (Fig. 5) that could be 
explored in clinical trials. In brief, patients with ERBB2 gene amplification but no overexpression of Her2 are 
likely best treated with alternative therapies. Patients with ERBB2 amplification and Her2 overexpression in asso-
ciation with other major genomic alterations but in the absence of SNVs in the extracellular domain may ben-
efit from TDM-1, the antibody drug-conjugate that requires Her2 overexpression for delivery of the cytotoxic 
payload, but is independent of Her2 pathway activity36. Finally, patients with ERBB2 gene amplification and 
protein overexpression in the absence of ERBB2 SNVs and other major genomic alterations may benefit most 
from trastuzumab or lapatinib (or other Her2-targeting tyrosine kinase inhibitors). As described above, muta-
tions in either the extracellular or intracellular domain may have implications for trastuzumab or tyrosine kinase 
inhibitors, respectively. We are aware that this blueprint must be clinically qualified, and remains speculative in 
the meantime.
Recently elucidated molecular subtypes of MIBC based on gene expression are providing a framework for 
dissecting bladder cancer biology 14,21–23. Our results reinforce the need to consider potential biomarkers in the 
context of molecular subtypes. We observed that ERBB2 amplification, mRNA expression and protein expression 
were all significantly higher in tumors with luminal characteristics (cluster I and II). It is entirely plausible that 
genuine biological differences between basal and luminal MIBC influenced the results of recent clinical trials20. 
For example, lapatinib was considered particularly desirable via its dual inhibition of Her1 and Her2. On this 
basis, Her1 and/or Her2 positive patients were selected by IHC for enrollment in this trial20. Even excluding the 
likelihood that Her1 and Her2 overexpressing MIBC are biologically distinct entities21–23, the overall survival 
differences between patients with basal (enriched with Her1 positive) and luminal (enriched with Her2 positive) 
MIBC would probably confound trial outcome interpretation. Underscoring this hypothesis is our result showing 
that despite their established and potent oncogenic effect, Her2 alterations were not associated with poor overall 
survival.
Our study is not without limitations that are mainly due to its retrospective character. The focus of this man-
uscript was not to investigate the prognostic impact of Her2 in MIBC but to elucidate the intricacies of Her2 
alterations at the DNA, RNA and protein levels, and highlight the significance of molecular subtypes in this 
context. The amplification rate of 19% in our NAC cohort is high compared to previous data including to our 
own experience of ERBB2 amplification in MIBC37. However, we were able validate our FISH data by genomic 
DNA sequencing. In addition, the threshold for ERBB2 amplification determined by FISH has been modified26. 
Figure 5. Potential algorithm for molecularly stratifying MIBC patients for Her2 targeted therapy. 
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According to the historical threshold, the amplification rate in our NAC cohort would be 12%, which is consistent 
with previous findings in MIBC.
Our study of ERBB2/Her2 is exemplary for the type of analysis that may be necessary also for other targets 
in MIBC. FGFR3 alterations, for example vary according to protein expression, mutation, gene fusion and copy 
number, and it is not clear which is most relevant for success of FGFR3-targeted therapy. This is in apparent 
contrast to the success of targeted therapy in breast and gastric cancer where exclusive evaluation of Her2 protein 
expression via IHC (at least in patients with score 3) is sufficient to prioritize patients for Her2 targeted therapy. It 
is plausibly explained in these cancers by high concordance between gene status determined by FISH and protein 
expression (87.5% in gastric cancer38 and breast cancer 87.3%39). Contrarily, this concordance is lower in MIBC, 
which also has a higher rate of alterations across the entire genome. This latter characteristic may make FISH or 
IHC alone insufficient for selection of MIBC patients for Her2 targeted therapy.
Conclusions
Assessment of Her2 alterations at the DNA, RNA and protein level provides a much more comprehensive insight 
into Her2 relevance as a driver gene and a therapeutic target in MIBC, than through FISH or IHC alone. The com-
plex molecular landscape of Her2 alteration has probably confounded previous clinical trials of Her2-targeted 
therapies, and improved patient selection accounting for multi-modal Her2 status and tumor molecular subtype 
will be essential for future clinical trial design.
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